Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

L. Reckamp, Karen; W. Redman, Mary; H. Dragnev, Konstantin; Minichiello, Katherine; C. Villaruz, Liza; A. Faller, Bryan; Al Baghdadi, Tareq; J. Hines, Susan; Everhart, Leah; Highleyman, Louise; A. Papadimitrakopoulou, Vassiliki; W. Neal, Joel; N. Waqar, Saiama; D. Patel, Jyoti; E. Gray, Jhanelle; R. Gandara, David; Kelly, Karen; S. Herbst, Roy

doi:10.1200/jco.22.00912

Public

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

Published in Journal of Clinical Oncology • Jun 3, 2022

Authors:

Karen L. Reckamp

Mary W. Redman

Konstantin H. Dragnev

Abstract

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types. METHODS In this randomiz...

Subject

Medicine

Docetaxel

Ramucirumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!